Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 9, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs for Dr. R Greig on November 4, 2005, at a price of $52.63 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investors to Verify
- The transaction involved a notional increase in Ordinary Share ADRs for Dr. R Greig.
- The transaction date was November 4, 2005, with a share price of $52.63.
- The filing was signed by Simon Bicknell, Company Secretary, on November 9, 2005.
- No financial performance data is included in this specific report.